Latest: AVM Biotechnology interviewed by KOMO 4 News - AVM0703 expected to be more effective than Oxford's trial results! Watch now!

AVM0703 could be the first choice for terminal, no-option cancer

Pharmacology
Cancer Models
Approval Process

Personal Mission

AVM0703 has FDA approval to proceed with clinical trials in R/R Non-Hodgkins Lymphoma